Mississippi Organ Recovery Agency

MISSISSIPPI ORGAN RECOVERY AGENCY, MS, FOR FACILITIES AND EQUIPMENT TO EXPAND CLINICAL ORGAN/TISSUE RECOVERY FACILITY. - SINCE OPENING ITS DONOR CARE UNIT (DCU) IN JANUARY 2017, MORA HAS PERFORMED MORE THAN 800 ORGAN RECOVERIES AND 3,000 TISSUE RECOVERIES WITHIN A PURPOSE-BUILT CLINICAL FACILITY THAT HAS BEEN SHOWN TO LOWER RECOVERY COSTS WHILE INCREASING ORGAN YIELD, CONSISTENT WITH PUBLISHED FINDINGS IN THE AMERICAN COLLEGE OF SURGEONS LITERATURE. THIS PROJECT REQUESTS $1,000,000 IN FUNDING FOR MOVABLE EQUIPMENT TO SUSTAIN AND EXPAND THAT CAPACITY ACROSS MORA’S STATEWIDE HOSPITAL NETWORK, ENSURING THE DCU KEEPS PACE WITH CLINICAL DEMAND AND TECHNOLOGICAL ADVANCES IN DONOR MANAGEMENT, ORGAN PRESERVATION, AND TISSUE RECOVERY. FUNDS WILL PURCHASE CLINICAL AND OPERATIONAL EQUIPMENT, INCLUDING HYPOTHERMIC KIDNEY PERFUSION PUMPS, A CRRT MACHINE, AN ECHOCARDIOGRAM MACHINE, VENTILATORS, A DIGITAL PATHOLOGY SCANNER AND CRYOSTAT, AN OR TABLE, DONOR CRITICAL CARE BEDS, BIOHAZARD COLLECTION SYSTEMS, AND A DONOR TRANSPORTATION VAN. EACH ITEM WAS SELECTED TO EXPAND DONOR MANAGEMENT CAPACITY, SHORTEN COLD ISCHEMIC TIME, IMPROVE ORGAN EVALUATION AND UTILIZATION, AND PROTECT STAFF AND DONOR SAFETY, DIRECTLY INCREASING THE NUMBER OF ORGANS AND TISSUES SUCCESSFULLY RECOVERED AND TRANSPLANTED. THE CLINICAL AND FINANCIAL CASE IS CLEAR: KIDNEY TRANSPLANTATION COSTS MEDICARE AN AVERAGE OF $28,553 PER YEAR, VERSUS $68,585 PER YEAR FOR DIALYSIS, A SAVINGS OF $40,032 PER PATIENT PER YEAR. OVER A NATIONAL AVERAGE 12.3-YEAR WAIT-TO-TRANSPLANT PERIOD, CUMULATIVE MEDICARE SAVINGS AVERAGE $480,383 PER PATIENT. MORA PROJECTS THE FUNDED EQUIPMENT WILL DRIVE APPROXIMATELY $500,000 IN ANNUAL MEDICARE SAVINGS THROUGH INCREASED DONATIONS AND TRANSPLANTS, RECOVERING THE FULL $1,000,000 APPROPRIATION IN ROUGHLY TWO YEARS, WITH SAVINGS COMPOUNDING THEREAFTER, INDEPENDENT OF THE IMMEASURABLE GAINS IN PATIENT QUALITY OF LIFE AND LIVES SAVED. THIS IS A MOVEABLE-EQUIPMENT-ONLY PROJECT REQUIRING NO CONSTRUCTION, SITE MODIFICATION, OR NEW HIRES, WHICH ELIMINATES COMMON START-UP DELAYS AND ENVIRONMENTAL/HISTORIC-PRESERVATION REVIEW REQUIREMENTS. MORA WILL EXECUTE THE FULL PROJECT WITHIN A FOUR-MONTH PERIOD OF PERFORMANCE, FROM AWARD ON SEPTEMBER 1, 2026 THROUGH COMPLETION BY DECEMBER 31, 2026, USING ITS EXISTING, ACCREDITED PROCURE-TO-PAY CONTROL ENVIRONMENT (IDEAGEN Q-PULSE QUALITY MANAGEMENT SYSTEM). A NAMED PROJECT TEAM, INCLUDING THE CEO, EVP/CFO, DIRECTOR OF FINANCE, AND CLINICAL FACILITY MANAGER, WILL EXECUTE TIERED-AUTHORIZATION PURCHASING, COMPETITIVE PROCUREMENT UNDER 2 CFR 200.317–200.327, THREE-WAY MATCH VERIFICATION, AND CAPITAL ASSET TRACKING, THEREBY SATISFYING THE INTERNAL-CONTROL STANDARDS OF 2 CFR 200.303. MORA WILL MEET ALL FEDERAL REPORTING OBLIGATIONS, INCLUDING THE SF-425, SEMI-ANNUAL PROGRESS REPORTS, THE SF-428 TANGIBLE PERSONAL PROPERTY REPORT, AND FINAL CLOSEOUT CERTIFICATION, AND ANTICIPATES THE ABILITY TO PURSUE EARLY CLOSEOUT GIVEN THE COMPRESSED, WELL-CONTROLLED IMPLEMENTATION TIMELINE. THIS INVESTMENT WILL DIRECTLY STRENGTHEN MISSISSIPPI’S ORGAN AND TISSUE DONATION INFRASTRUCTURE, REDUCE MEDICARE EXPENDITURES, AND SAVE AND IMPROVE THE LIVES OF PATIENTS AND FAMILIES ACROSS THE STATE.